Frequent mutations in regulators of the classical NF-κB pathway (MYD88, TNFAIP3, CD79A/B, CARD11) are recognized as a hallmark of ABC DLBCL patients [19,20,21,22,23], and inhibition of the classical NF-κB pathway induces cell death in ABC DLBCL cell lines [24]. The gene discussed is MYD88; the disease is diffuse large B-cell lymphoma.